252 related articles for article (PubMed ID: 21623185)
1. Immunohistochemical determination of ETS-1 oncoprotein expression in urothelial carcinomas of the urinary bladder.
Sari A; Calli A; Gorgel SN; Altinboga AA; Kara C; Dincel C; Cakalagaoglu F
Appl Immunohistochem Mol Morphol; 2012 Mar; 20(2):153-8. PubMed ID: 21623185
[TBL] [Abstract][Full Text] [Related]
2. Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expression.
Hagikura M; Murakumo Y; Hasegawa M; Jijiwa M; Hagiwara S; Mii S; Hagikura S; Matsukawa Y; Yoshino Y; Hattori R; Wakai K; Nakamura S; Gotoh M; Takahashi M
Pathol Int; 2010 Nov; 60(11):735-43. PubMed ID: 20946523
[TBL] [Abstract][Full Text] [Related]
3. Decreased RECK and Increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness.
Wittschieber D; Stenzinger A; Klauschen F; Stephan C; Jung K; Erbersdobler A; Rabien A
Pathobiology; 2011; 78(3):123-31. PubMed ID: 21613799
[TBL] [Abstract][Full Text] [Related]
4. Fascin determination in urothelial carcinomas of the urinary bladder: a marker of invasiveness.
Karasavvidou F; Barbanis S; Pappa D; Moutzouris G; Tzortzis V; Melekos MD; Koukoulis G
Arch Pathol Lab Med; 2008 Dec; 132(12):1912-5. PubMed ID: 19061289
[TBL] [Abstract][Full Text] [Related]
5. CD 10 expression intensity in various grades and stages of urothelial carcinoma of urinary bladder.
Atique M; Abbasi MS; Jamal S; Khadim MT; Akhtar F; Jamal N
J Coll Physicians Surg Pak; 2014 May; 24(5):351-5. PubMed ID: 24848395
[TBL] [Abstract][Full Text] [Related]
6. IMP3 expression in urothelial carcinomas of the urinary bladder.
Ozdemir NO; Türk NS; Düzcan E
Turk Patoloji Derg; 2011 Jan; 27(1):31-7. PubMed ID: 21469424
[TBL] [Abstract][Full Text] [Related]
7. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.
Dickinson AJ; Fox SB; Newcomb PV; Persad RA; Sibley GN; Harris AL
J Urol; 1995 Jul; 154(1):237-41. PubMed ID: 7776437
[TBL] [Abstract][Full Text] [Related]
8. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
[TBL] [Abstract][Full Text] [Related]
9. Urachal carcinomas of the nonglandular type: salient features and considerations in pathologic diagnosis.
Paner GP; Barkan GA; Mehta V; Sirintrapun SJ; Tsuzuki T; Sebo TJ; Jimenez RE
Am J Surg Pathol; 2012 Mar; 36(3):432-42. PubMed ID: 22301493
[TBL] [Abstract][Full Text] [Related]
10. Beclin 1 and bcl-2 expressions in bladder urothelial tumors and their association with clinicopathological parameters.
Baspinar S; Bircan S; Yavuz G; Kapucuoglu N
Pathol Res Pract; 2013 Jul; 209(7):418-23. PubMed ID: 23722017
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of p63, p53 in urinary bladder carcinoma.
Koyuncuer A
Indian J Pathol Microbiol; 2013; 56(1):10-5. PubMed ID: 23924551
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
Chang WC; Chang YH; Pan CC
Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases.
Compérat E; Camparo P; Haus R; Chartier-Kastler E; Bart S; Delcourt A; Houlgatte A; François R; Capron F; Vieillefond A
Virchows Arch; 2006 Mar; 448(3):319-24. PubMed ID: 16283378
[TBL] [Abstract][Full Text] [Related]
14. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
[TBL] [Abstract][Full Text] [Related]
15. Inducing cell proliferation inhibition, apoptosis, and motility reduction by silencing long noncoding ribonucleic acid metastasis-associated lung adenocarcinoma transcript 1 in urothelial carcinoma of the bladder.
Han Y; Liu Y; Nie L; Gui Y; Cai Z
Urology; 2013 Jan; 81(1):209.e1-7. PubMed ID: 23153939
[TBL] [Abstract][Full Text] [Related]
16. ETS-1 proto-oncogene as a key newcomer molecule to predict invasiveness in laryngeal carcinoma.
Calli AO; Sari A; Cakalagaoglu F; Altinboga AA; Oncel S
Pathol Res Pract; 2011 Oct; 207(10):628-33. PubMed ID: 21940109
[TBL] [Abstract][Full Text] [Related]
17. High expression of Notch ligand Jagged2 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.
Li W; Liu M; Feng Y; Huang YF; Xu YF; Che JP; Wang GC; Zheng JH
Int J Clin Exp Pathol; 2013; 6(11):2430-40. PubMed ID: 24228105
[TBL] [Abstract][Full Text] [Related]
18. Measuring the dimension of invasive component in pT1 urothelial carcinoma in transurethral resection specimens can predict time to recurrence.
Hu Z; Mudaliar K; Quek ML; Paner GP; Barkan GA
Ann Diagn Pathol; 2014 Apr; 18(2):49-52. PubMed ID: 24370460
[TBL] [Abstract][Full Text] [Related]
19. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.
Caprodossi S; Lucciarini R; Amantini C; Nabissi M; Canesin G; Ballarini P; Di Spilimbergo A; Cardarelli MA; Servi L; Mammana G; Santoni G
Eur Urol; 2008 Sep; 54(3):612-20. PubMed ID: 17977643
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth.
Gómez-Román JJ; Saenz P; Molina M; Cuevas González J; Escuredo K; Santa Cruz S; Junquera C; Simón L; Martínez A; Gutiérrez Baños JL; López-Brea M; Esparza C; Val-Bernal JF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):459-65. PubMed ID: 15701828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
